Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 109
Posts 24,075
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/30/2020 7:08:57 AM
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Business Wire - 6/30/2020 7:00:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 6/19/2020 4:36:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 4:24:38 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 6:03:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2020 8:30:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:04:03 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:11:22 AM
Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire - 6/10/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/9/2020 7:05:20 AM
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire - 6/9/2020 7:00:00 AM
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire - 6/8/2020 7:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2020 7:22:28 AM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial & Registration Plan for ... Business Wire - 6/4/2020 7:14:00 AM
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire - 6/3/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/1/2020 7:24:12 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:07:32 AM
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 6/1/2020 7:00:00 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire - 5/28/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:13:58 AM
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... Business Wire - 5/21/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:09:21 AM
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... Business Wire - 5/18/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/15/2020 7:29:18 AM
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Modera... Business Wire - 5/15/2020 7:00:00 AM
midastouch017   Thursday, 04/16/20 10:46:07 AM
Re: None
Post # of 1449 
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will conduct a conference call with investors to review the results of its Phase II exploratory NAFLD/NASH study with Namodenoson which achieved its primary and secondary efficacy endpoints, while showing continued safety.
Top-line results from the Phase II double-blind, placebo-controlled, dose-finding efficacy and safety study which enrolled 60 patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH), were announced on April 7, 2020 and can be found here.
Call Information
Date: Thursday, April 16, 2020
Time: 4:05 p.m. ET

Dial-in U.S.: 1-877-423-9813
Dial-in Israel: 1-201-689-8573
Conference ID: 13702174
Webcast: http://public.viavid.com/index.php?id=139178
Can-Fite CEO, Dr. Pnina Fishman will give an introduction, followed by a presentation of the data by the study’s Principal Investigator Dr. Rifaat Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. Commenting on the data will be Dr. Scott Friedman, a key opinion leader in NASH and Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York City. The next steps in the clinical development of Namodenoson for the treatment of NASH will be discussed. The presentation will be followed by a Q&A session.
The investor call will be accessible through the New/Events section of Can-Fite’s website at www.canfite.com where it will be archived for a period of time.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist